AnaptysBio (ANAB) Stock Price, News & Analysis

Company Overview

AnaptysBio, Inc. is a clinical-stage biotechnology company focused on the discovery and development of therapeutic antibody product candidates in immunology and inflammation. Founded in 2012 and headquartered in San Diego, California, AnaptysBio leverages a proprietary somatic hypermutation platform to rapidly generate and refine human antibodies with optimized efficacy and safety profiles. The company's technology is designed to accelerate target validation and candidate selection across a range of immune-mediated conditions.

The company’s pipeline includes multiple clinical-stage programs addressing dermatological and inflammatory disorders. Among its leading candidates is ANB020, an anti-IL-33 antibody being evaluated for atopic dermatitis and eosinophilic asthma, and ANB019, an anti-IL-36 receptor antibody in development for generalized pustular psoriasis. In addition to its clinical assets, AnaptysBio is advancing several preclinical programs aimed at novel immuno-oncology targets, reflecting its commitment to broadening the therapeutic potential of its platform.

AnaptysBio has established strategic partnerships to enhance its research and development efforts. These collaborations include agreements with major pharmaceutical companies to co-develop and commercialize select antibody candidates. Through these alliances, AnaptysBio gains access to expanded development expertise, global regulatory capabilities, and commercialization support, while retaining rights to key programs emerging from its discovery engine.

Since completing its initial public offering in 2016, AnaptysBio has grown its team and infrastructure to support both early-stage discovery and late-stage clinical development. The company is led by President and Chief Executive Officer Hamza Suria and maintains research operations in the United States. AnaptysBio’s mission is to deliver differentiated antibody therapeutics that address unmet medical needs in inflammatory diseases and cancer.

Key Stats

• Today's Range: $22.01 to $22.69
• 50-Day Range: $19.79 to $27.00
• 52-Week Range: $12.21 to $40.70
• Volume: 276,895 shs
• Average Volume: 735,550 shs
• Market Capitalization: $629.58 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $46.13
• Consensus Rating: Moderate Buy

AnaptysBio Stock Analysis - MarketRank™

AnaptysBio scored higher than 52% of companies evaluated by MarketBeat, and ranked 514th out of 923 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.0 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

AnaptysBio has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on 6 buy ratings, 3 hold ratings, and no sell ratings.

Upside Potential

AnaptysBio has a consensus price target of $46.13, representing about 104.0% upside from its current price of $22.61.

Amount of Analyst Coverage

AnaptysBio has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for AnaptysBio are expected to grow in the coming year, from ($6.08) to ($5.36) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of AnaptysBio is -5.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of AnaptysBio is -5.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

AnaptysBio has a P/B Ratio of 9.70. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 0.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

37.51% of the float of AnaptysBio has been sold short.

Short Interest Ratio / Days to Cover

AnaptysBio has a short interest ratio ("days to cover") of 16.7, which indicates bearish sentiment.

Change versus previous month

Short interest in AnaptysBio has recently increased by 0.42%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

AnaptysBio does not currently pay a dividend.

Dividend Growth

AnaptysBio does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

37.51% of the float of AnaptysBio has been sold short.

Short Interest Ratio / Days to Cover

AnaptysBio has a short interest ratio ("days to cover") of 16.7, which indicates bearish sentiment.

Change versus previous month

Short interest in AnaptysBio has recently increased by 0.42%, indicating that investor sentiment is decreasing.

News and Social Media

• Score: 3.7 / 5
• News Sentiment: 1.57

News Sentiment

AnaptysBio has a news sentiment score of 1.57. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.84 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 8 news articles for AnaptysBio this week, compared to 5 articles on an average week.

Search Interest

4 people have searched for ANAB on MarketBeat in the last 30 days. This is an increase of 33% compared to the previous 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, AnaptysBio insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $493,202.00 in company stock.

Percentage Held by Insiders

33.50% of the stock of AnaptysBio is held by insiders. A high percentage of insider ownership can be a sign of company health.

ANAB Stock Analysis - Frequently Asked Questions

How have ANAB shares performed this year?

AnaptysBio's stock was trading at $13.24 on January 1st, 2025. Since then, ANAB stock has increased by 70.8% and is now trading at $22.61.

How were AnaptysBio's earnings last quarter?

AnaptysBio, Inc. (NASDAQ:ANAB) posted its earnings results on Wednesday, August, 6th. The biotechnology company reported ($1.34) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.50) by $0.16. The biotechnology company earned $22.26 million during the quarter, compared to the consensus estimate of $11.55 million. AnaptysBio had a negative trailing twelve-month return on equity of 366.98% and a negative net margin of 107.66%.

Is AnaptysBio buying back stock?

AnaptysBio's board approved a share repurchase plan on Monday, March 24th 2025, which authorizes the company to buy back $75,000,000 in shares, according to EventVestor. This means that the company could buy up to 13.1% of its stock through open market purchases. Stock repurchase plans are typically a sign that the company's board believes its stock is undervalued.

When did AnaptysBio IPO?

AnaptysBio (ANAB) raised $60 million in an IPO on Thursday, January 26th 2017. The company issued 4,000,000 shares at a price of $14.00-$16.00 per share. Credit Suisse and Stifel served as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers.

Who are AnaptysBio's major shareholders?

AnaptysBio's top institutional investors include First Light Asset Management LLC (12.64%), Bank of America Corp DE (3.85%), Sofinnova Investments Inc. (3.69%) and 683 Capital Management LLC (1.79%). Insiders that own company stock include Ecor1 Capital, Llc, Daniel Faga, Paul F Lizzul, Eric J Loumeau, Hollings Renton, Dennis Mulroy and Dennis M Fenton.
View institutional ownership trends.

How do I buy shares of AnaptysBio?

Shares of ANAB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of AnaptysBio own?

Based on aggregate information from My MarketBeat watchlists, some other companies that AnaptysBio investors own include Meta Platforms (META), NVIDIA (NVDA), Tesla (TSLA), Alibaba Group (BABA), Advanced Micro Devices (AMD), Moderna (MRNA) and Alphabet (GOOG).

Company Calendar

• Last Earnings: 8/06/2025
• Today: 9/10/2025
• Next Earnings (Estimated): 11/04/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:ANAB
• CIK: 1370053
• Web: www.anaptysbio.com
• Phone: (858) 362-6295
• Fax: N/A
• Employees: 100
• Year Founded: 2005

Price Target and Rating

• Average Price Target for AnaptysBio: $46.13
• High Price Target: $90.00
• Low Price Target: $20.00
• Potential Upside/Downside: +105.3%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.80
• Research Coverage: 10 Analysts

Profitability

• EPS (Trailing Twelve Months): ($4.48)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$145.23 million
• Net Margins: -107.66%
• Pretax Margin: -107.59%
• Return on Equity: -366.98%
• Return on Assets: -30.58%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 8.22
• Quick Ratio: 8.22

Sales & Book Value

• Annual Sales: $91.28 million
• Price / Sales: 6.89
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.33 per share
• Price / Book: 9.64

Miscellaneous

• Outstanding Shares: 28,000,000
• Free Float: 18,618,000
• Market Cap: $629.02 million
• Optionable: Optionable
• Beta: -0.19